Cara Therapeutics Files Q2 2024 10-Q

TL;DR

Cara Therapeutics Q2 10-Q filed. Financials look steady.

AI Summary

Cara Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second quarter. Key financial figures and balance sheet items are presented, reflecting the company's ongoing activities in the pharmaceutical sector.

Why It Matters

This filing provides investors with the latest financial health and operational status of Cara Therapeutics, crucial for understanding its market position and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Cara Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 548,377,64 — Common Stock Value (Represents the value of common stock for the period ending June 30, 2024.)
• 54,480,704 — Common Stock Value (Represents the value of common stock for the period ending March 31, 2024.)

Key Players & Entities

• Cara Therapeutics, Inc. (company) — Filer of the 10-Q
• 20240630 (date) — End of the reporting period
• 20240814 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CARA The Nasdaq Stock Mar

Filing Documents

• cara-20240630x10q.htm (10-Q) — 2564KB
• cara-20240630xex31d1.htm (EX-31.1) — 12KB
• cara-20240630xex31d2.htm (EX-31.2) — 11KB
• cara-20240630xex32d1.htm (EX-32.1) — 11KB
• 0001558370-24-012231.txt ( ) — 9908KB
• cara-20240630.xsd (EX-101.SCH) — 65KB
• cara-20240630_cal.xml (EX-101.CAL) — 56KB
• cara-20240630_def.xml (EX-101.DEF) — 297KB
• cara-20240630_lab.xml (EX-101.LAB) — 517KB
• cara-20240630_pre.xml (EX-101.PRE) — 447KB
• cara-20240630x10q_htm.xml (XML) — 1763KB

–FINANCIAL INFORMATION

PART I –FINANCIAL INFORMATION PAGE NUMBER Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) : Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 1 Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023 2 Condensed Consolidated Statements of Stockholders' Equity for the Three and Six Months Ended June 30, 2024 and 2023 3 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 29 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 55 Item 4.

Controls and Procedures

Controls and Procedures 56

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 57 Item 1A .

Risk Factors

Risk Factors 57 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 100 Item 3. Defaults Upon Senior Securities 100 Item 4. Mine Safety Disclosures 100 Item 5. Other Information 100 Item 6. Exhibits 101

SIGNATURES

SIGNATURES 102 Table of Contents PART I FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements . CARA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (amounts in thousands, excluding share and per share data) (unaudited) June 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 49,239 $ 51,775 Marketable securities 7,379 48,983 Accounts receivable, net - related party 359 2,765 Inventory, net 1,644 2,821 Income tax receivable 697 697 Other receivables 764 555 Prepaid expenses 3,777 8,154 Restricted cash — 408 Total current assets 63,859 116,158 Operating lease right-of-use assets 3,646 4,864 Property and equipment, net 3,490 3,322 Restricted cash, non-current 1,500 1,500 Total assets $ 72,495 $ 125,844 Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses $ 13,733 $ 25,592 Operating lease liability, current 168 — Total current liabilities 13,901 25,592 Liability related to sales of future royalties and milestones, net 39,676 37,079 Operating lease liability, non-current 7,320 6,088 Total liabilities 60,897 68,759 Commitments and contingencies (Note 17) — — Stockholders' equity: Preferred stock; $ 0.001 par value; 5,000,000 shares authorized at June 30, 2024 and December 31, 2023, zero shares issued and outstanding at June 30, 2024 and December 31, 2023 — — Common stock; $ 0.001 par value; 200,000,000 shares and 100,000,000 shares authorized at June 30, 2024 and December 31, 2023, respectively, 54,837,764 shares and 54,480,704 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 54 54 Additional paid-in capital 747,122 742,036 Accumulated deficit ( 735,457 ) ( 684,745 ) Accumulated other comprehensive loss ( 121 ) ( 260 ) Total stockholders' equity 11,598 57,085 Total liabilities and stockholders' equity $ 72,495 $ 125,844 See Notes to Condensed Consolidated Financial Stateme

View Full Filing

View this 10-Q filing on SEC EDGAR